About miglitolalpha-glucosidase inhibitor,piperidine derivative, oral anti-diabetic drug.mechanism of action of miglitolthe drug exerts it`s antihyperglycaemic action by causing reversible competitive inhibition of membrane bound intestinal alpha-glucosidase hydrolase enzymes- which are the final enzymes in the carbohydrate digestion in the brush border of small intestinal mucosa. it also inhibits sucrase and weak inhibitory effects on pancreatic a-amylase and reduces digestion and absorption of polysaccharides and sucrose, lowers hba1c, body weight and serum triglyceride levels. it delays and reduces glucose absorption and lowers postprandial hyperglycaemia.indications for miglitolas monotherapy as an adjunct to diet to improve glycemic control in patients with type 2 diabetes. can be used in combination with sulphonylurea, metformin and/or insulin.
Voir plus de détails